Therefore, DNA repair proteins, XRCC1 and PARP1, have been associated with significantly aggressive clinical outcome of ovarian cancer patients and decreased cisplatin sensitivity in OC cells. The gene discussed is PARP1; the disease is ovarian carcinoma.